Arrowhead Pharmaceuticals, Inc. Overview
Pro stress-test →Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them using a broad portfolio of RNA chemistries and efficient modes of delivery. The company received its first FDA regulatory approval in November 2025 and began the next phase of growth as a commercial company marketing its own medicines. With a market capitalization of $9.05 billion, the company operates within the biotechnology industry.
Strategic Profile
Pro stress-test →The company received regulatory approval for REDEMPLO in familial chylomicronemia syndrome in three different countries and launched its first commercial product in the U.S. Arrowhead received a $200 million upfront payment from Novartis and is eligible to receive development, regulatory, and sales milestone payments of up to $2 billion with tiered royalties on commercial sales up to the low double digits. The company has demonstrated significant revenue growth with a 3-year revenue growth rate of 39%.
Competitive Landscape
Pro stress-test →Arrowhead is an American biotechnology company focused on developing medicines for diseases with genetic origin, with portfolio targeting cardiovascular, cardiometabolic, central nervous system, pulmonary, liver, muscular, and complement-mediated diseases. The company competes with other RNAi therapeutics developers including Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Wave Life Sciences in the gene-silencing space.
Industry Context
Arrowhead Pharmaceuticals, Inc. operates in Biotechnology / RNA Therapeutics.
Key facts
Founded: 2008 · Headquarters: Pasadena, US · Revenue: $264M (Q1 FY2026) · Market cap: $9.05B